Sanofi account plan
AI-powered biopharma company
At a glance
Sanofi is a Paris-based biopharma company in immunology, rare diseases and vaccines, with €43,626m 2025 net sales led by Dupixent and 74,846 employees.
Sanofi is a Paris-based biopharma company that reports a single Biopharma segment run through Specialty Care, General Medicines and Vaccines, with research centred on immunology. It has business operations in about 60 countries, sells in more than 160 and ranks as the ninth-largest pharmaceutical company globally; the US was 50.8% of 2025 sales. FY2025 net sales were €43,626m (+9.9% at constant exchange rates), business operating income €12,149m and IFRS net income €7,813m, with Dupixent alone at €15,714m. Headcount was 74,846 at end-2025 after the consumer health business Opella was deconsolidated in April 2025; Sanofi keeps a 48.2% stake in it.
Business units
Specialty Care
Immunology, rare diseases, neurology and oncology, including Dupixent (€15,714m in 2025, with Regeneron), ALTUVIIIO, Nexviazyme, Ayvakit and Sarclisa. It had 8,291 employees at end-2025 and is led by Manuela Buxo since 1 March 2026.
General Medicines
Established brands such as Lantus, Toujeo, Plavix, Lovenox and Praluent, plus Rezurock and Tzield, with 19 industrial sites. Mature products face generic and biosimilar erosion and US price cuts. Thomas Grenier leads it from 1 September 2026.
Vaccines
€7,936m FY2025 net salesPolio/pertussis/Hib and boosters, influenza and COVID-19, Beyfortus (RSV, with AstraZeneca) and meningitis, travel and endemic vaccines, sold to governments and buyers such as UNICEF and GAVI. Sales fell 1.2% at CER in 2025 and the Dynavax acquisition added Heplisav-B in 2026. Led by Thomas Triomphe until he moves to lead China on 1 September 2026.
Strategic priorities
- Maximise Dupixent
- Dupixent is expected to reach around €25bn in 2030; a Defend, Extend, Innovate plan targets protection beyond the March 2031 US compound patent expiry, including four-weekly dosing.
- Grow pharma launches
- Pharma launches are targeted at about €10bn by 2030 and €5.2-5.3bn in 2026, led by ALTUVIIIO, Sarclisa, Ayvakit, Nexviazyme and Rezurock.
- Fix R&D productivity
- CEO Belén Garijo launched an outside-in portfolio review that has already cut amlitelimab, itepekimab and balinatunfib, and wants more scientific rigor in Phase 2-to-Phase 3 decisions.
- Intensify business development and M&A
- Sanofi could invest up to €15 billion in BD and M&A this year while keeping its AA rating, focusing on dermatology, respiratory and rare diseases; bigger deals are an option.
- Regain momentum in China
- Thomas Triomphe leads China from 1 September 2026, to sell into the market and in-license Chinese innovation.
- AI-powered efficiency
- The Plai decision platform is used by 22,000+ employees and the Concierge GenAI tool has 30,000 users; efficiency savings fund R&D.
Latest results
In H1 2026 net sales rose 15.7% at CER to €22,106m, driven by Dupixent (€9,324m, +34.4%), ALTUVIIIO and Ayvakit, while vaccines fell 1.1%. Business operating income grew 16.7% to €6,258m and business EPS 17.1% to €3.97, but IFRS net income fell to €1,957m after a €952m amlitelimab impairment and restructuring. In Q2 2026 Dupixent passed €5bn in a quarter for the first time, at €5,154m. Net debt rose to €15,513m after the Dynavax acquisition, the dividend and buybacks. Guidance was raised to around 10% sales growth at CER in 2026, with business EPS growing slightly faster.
Investments and deals
- 2025 acquisitions
- Blueprint Medicines (~$9.1bn equity), Vicebio ($1.15bn upfront), Vigil Neuroscience (~$470m) and Dren-0201 (€539m upfront); acquisitions above €500m used €10,986m of cash.
- Dynavax
- Closed on 10 February 2026 for ~$2.2bn, adding the Heplisav-B hepatitis B vaccine and a shingles candidate.
- US manufacturing commitment
- Under the 19 December 2025 MFN agreement Sanofi reaffirmed a $20bn US manufacturing investment in exchange for a three-year tariff exemption.
- Capex and buybacks
- Capex of €1,762m in property, plant and equipment in 2025, with about €1.75bn a year expected in the medium term; a €1bn buyback was completed in April 2026.
- Divestments
- Opella's 50% controlling stake was sold to CD&R for €10.4bn net cash, Enjaymo went to Recordati, and the Brazilian generics unit Medley is being sold.
Challenges and risks
- US drug pricing
- The MFN agreement brings 61% price cuts on selected drugs and a $35 insulin cap, and the CMS GLOBE and GUARD models could have a material adverse effect.
- Pipeline setbacks
- Impairments on tolebrutinib (€1,663m) in 2025 and amlitelimab (€952m) in 2026, plus discontinued programmes, put R&D productivity under scrutiny.
- Dupixent concentration
- The group depends heavily on Dupixent, which faces the March 2031 US compound patent expiry; Regeneron profit-sharing reached €5,065m in 2025.
- Weak vaccines and China
- Vaccines are expected slightly negative in 2026 on weaker US vaccination rates, and China sales fell 3.5% in H1 2026 as fewer births hit paediatric vaccines.
- Generic erosion and Regeneron reimbursement
- Generic erosion cost €353m of sales in 2025, and the end of Regeneron development reimbursement leaves a €200m net BOI gap in 2027.
What leadership says
“My first months as CEO have focused on assessing the challenges facing Sanofi and working on an accelerated transformation roadmap that leverages our commercial strengths and focuses on the need for R&D and pipeline improvements”
“It is also absolutely imperative that we intensify our business development and M&A activity in a disciplined way.”
“Our current focus is Dupixent, one. Two, Dupixent. Three, Dupixent.”
“take some time to make the right diagnostic”
Where a supplier can help
- Clinical operations and trial design
- The push for R&D rigor and end-to-end clinical operations from study design to trial conclusion opens room for CROs, trial analytics and decision-support tools.
- Licensing and BD support
- Intensified BD and M&A, including in-licensing Chinese innovation, needs scientific due diligence, deal advisory and alliance management partners.
- US manufacturing capacity
- The reaffirmed $20bn US manufacturing investment points to demand for biologics plant engineering, equipment and contract manufacturing.
- Market access and pricing analytics
- MFN pricing, IRA negotiation and CMS models raise the need for gross-to-net, rebate and market access analytics.
- AI and data platforms
- Sanofi's AI-powered efficiency agenda, with Plai and GenAI tools in wide use, favours AI, data and automation providers across R&D and manufacturing.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Sanofi?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 20-F 2025
- Sanofi describes itself as "an R&D driven, AI-powered biopharma company"; it reports a single operating segment, Biopharma (Specialty Care, General Medicines and Vaccines franchises), organised around Immunology, Rare Diseases, Neurology, Oncology, Other Medicines and Vaccines. Consumer healthcare (Opella) was deconsolidated on 30 April 2025: a 50% controlling stake sold to CD&R, Sanofi keeps 48.2%, €10.4bn net cash proceeds, €2.6bn net gain.
- FY2025 net sales €43,626m, +6.2% reported and +9.9% at constant exchange rates (CER); business operating income €12,149m (vs €11,343m); business net income €9,555m (+7.2%); business EPS €7.83 (+10.0%); IFRS net income €7,813m (EPS €6.40, including the Opella gain); proposed dividend €4.12 per share (52.6% payout).
- Dupixent (with Regeneron) is the engine: €15,714m, +25.2% CER (US €11,538m, +26.7%); the US is 50.8% of group sales (€22,176m, +16.3% CER) while Europe is €9,169m (+1.6%) and Rest of World €12,281m (+5.6%, China €2,621m, +2.0%). Regeneron profit-sharing and related expenses reached €5,065m.
- Launches generated €5,721m (+34.0% CER): ALTUVIIIO €1,160m (+77.6%), Nexviazyme €790m (+21.4%), Sarclisa €588m (+28.5%), Rezurock €490m, Ayvakit €305m (consolidated since mid-July 2025), Cablivi €271m, Xenpozyme €228m. Vaccines were €7,936m (-1.2% CER): Beyfortus €1,781m (+9.5%), influenza/COVID €2,314m (-5.8%), PPH & boosters €2,554m (-4.4%).
- 2025 was an acquisition year: Blueprint Medicines (~$9.1bn equity, up to $9.5bn with CVRs), Vicebio ($1.15bn upfront), Vigil (~$470m), Dren-0201 (€539m upfront, up to €1.2bn milestones), plus the agreed Dynavax deal (~$2.2bn, closing Q1 2026); acquisitions above €500m consumed €10,986m of cash. €5bn of buybacks (incl. €3bn from L'Oréal) and €4,772m of dividends; net debt rose to €11,008m (gearing 15.4%); free cash flow €8,089m (vs €5,955m).
- Strategy ("Play to Win", relaunched in 2025 as "Take the Lead"): focus on growth (Dupixent, launches, four vaccine franchises), lead with innovation (immunology-centred "immuno-science" R&D, external deals), accelerate efficiency (AI platform Plai used by 22,000+ employees; GenAI Concierge 30,000 users) and reinvent how we work. Capital allocation order: organic growth, bolt-on BD/M&A, growing dividend, anti-dilutive buybacks.
- R&D spend €7,842m (18.0% of sales; 9,274 R&D employees out of 74,846 staff); 2025 pipeline readouts included positive Phase 3s for amlitelimab in atopic dermatitis and a €1,663m impairment on tolebrutinib after the failed PERSEUS study in PPMS.
- Headwinds flagged for 2026: the voluntary US "most favored nation" agreement signed 19 December 2025 (Medicaid prices aligned with high-income countries, 61% average cuts on selected diabetes/cardiovascular/neurology/cancer drugs, up to 70% discounts via TrumpRx, $35 insulin cap, in exchange for a three-year tariff exemption and a reaffirmed $20bn US manufacturing investment), IRA Medicare negotiation, CMS GLOBE/GUARD models, generic erosion (€353m lost in 2025), China VBP tenders and shifting US vaccine policy.
- Operations: ~60 countries with business operations, products in 160+ countries, ninth-largest pharma group by sales (US rank 12, 2.2% share; France rank 6, 4.0%); most production in-house, 37 industrial sites in 19 countries, vaccine sites in France, the US, Canada, India, Mexico and China.
- Leadership change recorded in the filing: on 11 February 2026 the Board relieved Paul Hudson of his duties as CEO effective 17 February 2026 and appointed Belén Garijo to succeed him after the 29 April 2026 AGM; Olivier Charmeil (EVP General Medicines) serves as interim CEO from 18 February; the Executive Committee has 12 members as of 17 February 2026.
- Half-Year Financial Report 2026
- H1 2026 net sales €22,106m, +11.1% reported and +15.7% at CER (currency cost 4.6 points), driven by Dupixent (€9,324m, +34.4% CER), Ayvakit (€367m) and ALTUVIIIO (€674m, +32.3%); launches reached €3,047m (+51.8%).
- Business operating income €6,258m (+16.7%, 28.3% of sales); business net income €4,765m (+14.8%); business EPS €3.97 (+17.1%). IFRS net income fell to €1,957m from €5,812m because H1 2025 carried the €2,693m Opella gain and H1 2026 carries a €952m amlitelimab impairment and €563m of restructuring; IFRS EPS €1.63.
- Geography: US €11,633m (+29.9% CER), Europe €4,304m (+3.6%), Rest of World €6,169m (+1.9%), China €1,325m (-3.5%, falling birth rate hitting paediatric vaccines). Vaccines €2,443m (-1.1%): PPH incl. newly acquired Heplisav-B €1,364m (+2.8%), Beyfortus €392m (+13.2%), influenza/COVID €121m (-42.1%).
- Cash and balance sheet: free cash flow €3,724m (€2,458m); net debt up to €15,513m from €11,008m after the Dynavax acquisition (€1,403m cash), the €4,923m dividend and €1,003m of buybacks (12.57m shares); gearing 22.3%; €2.3bn bond issued in April; equity €69,567m.
- Governance reset: the Board did not renew Paul Hudson (CEO relieved 17 February 2026), Olivier Charmeil served as interim CEO from 18 February to 30 April, Belén Garijo is CEO since 1 May 2026; the AGM of 29 April approved a €4.12 dividend; a slimmer eight-member Executive Committee applies from 1 September 2026 (Roger finance, Paulo Fontoura R&D, Buxo specialty care, Triomphe vaccines, Grenier general medicines, O'Callaghan manufacturing, Haney legal, Jaillet interim people).
- Pipeline decisions: amlitelimab will not be filed (24 July 2026); itepekimab (COPD, CRS) discontinued with Regeneron; riliprubart MOBILIZE stopped; Dupixent failed in lichen simplex chronicus and the EU bullous pemphigoid file was withdrawn. Positives: Dupixent approvals in AFRS (US) and paediatric CSU (US/EU), Tzield expansions, Cenrifki approved in the EU for non-relapsing SPMS, Sarclisa subcutaneous approved in the EU, US and Japan, Nexviazyme Baby-COMET success, venglustat priority review (FDA date 25 November 2026), efdoralprin alfa filing planned H2 2026.
- Outlook raised: 2026 sales now expected to grow around 10% at CER, business EPS slightly faster; currency impact estimated at about -1% on sales and -2% on business EPS at July 2026 rates. R&D €3,980m (18.0% of sales, including over €200m of wind-down costs), SG&A €4,792m (21.7%).
- Access and sustainability: Impact not-for-profit medicines now in 30 countries, Global Health Unit reaching 6.6m beneficiaries across 40 countries; acoziborole (single-dose sleeping sickness treatment) approved in the DRC; Action 2026 employee share plan offered to ~75,000 employees in 52 countries at €59.87.
- Q2 2026 results press release: double-digit sales growth, 2026 guidance upgraded
- Q2 2026 net sales €11,597m, +17.8% at CER (+16.0% reported); business operating income €3,291m (+35.8%, margin 28.4%, +3.8 points); business EPS €2.09 (+33.3% CER); IFRS EPS €0.29 (net income €343m, -91.3%, after a €1,031m impairment mainly on amlitelimab and €444m of restructuring); free cash flow €2,670m (+86.8%).
- Dupixent €5,154m (+37.6%), above €5bn in a quarter for the first time; US €3,899m (+42.8%) helped by demand, operational improvements and a favourable gross-to-net adjustment; Europe €583m (+19.4%); Rest of World €672m (+26.9%).
- Pharma launches €1,305m (+48.3%): ALTUVIIIO €349m (+23.7%), Sarclisa €187m (+35.7%), Ayvakit €190m ($221.3m, +26.4% pro forma, held back by higher US rebates), Nexviazyme €218m, Rezurock €163m, Cablivi €85m, Wayrilz €17m, Qfitlia €7m. Vaccines €1,150m (-4.7%): influenza/COVID €54m (-61.7%) on 2025 one-offs, Beyfortus €108m (+54.2%), PPH incl. Heplisav-B €700m (+1.4%; US +77.2%).
- Geography: US €6,344m (+33.5%), Europe €2,141m (+1.3%), Rest of World €3,112m (+3.7%), China €676m (-4.9%, paediatric vaccines hit by fewer births; pharma up low single digits on Sarclisa, Rezurock, Myqorzo and Dupixent).
- Costs: R&D €2,233m (+17.9%, including over €200m of pipeline wind-down costs), SG&A €2,465m (+9.0%, Blueprint and Dynavax consolidation); gross margin 81.2% (+3.7 points, including a >€200m Sarclisa SC provision reversal); Regeneron profit-sharing €1,972m; effective tax rate 21.7%, now expected around 21% for 2026.
- Pipeline: seven approvals (Dupixent paediatric CSU in the US, Tzield stage 3 T1D in the US, Wayrilz ITP in Japan, Sarclisa SC in the US, EU and Japan, Cenrifki SPMS in the EU), submissions accepted for Dupixent AFRS in Japan and venglustat GD3 in the US, EU and Japan, positive Phase 3s for Nexviazyme (infantile Pompe) and amlitelimab maintenance, but amlitelimab will not be filed and itepekimab and balinatunfib are discontinued; Dupixent failed in lichen simplex chronicus; venglustat has an FDA action date of 25 November 2026; 61 projects in the pipeline, 36 of them new molecular entities.
- Guidance upgraded: 2026 sales growth around 10% at CER (from high single digits), business EPS slightly faster than sales; currency about -1% on sales and -2% on EPS. CEO Belén Garijo cites an "accelerated transformation roadmap" and a 2030 ambition of around €25bn Dupixent sales plus about €10bn from pharma launches.
- Capital: €1bn buyback completed in April; dividend €4.12 (31 consecutive increases); net debt €15,513m at 30 June (from €10,988m) after Dynavax (€1,635m), buyback (€1,009m) and the €4,923m dividend; Q3 2026 results due 30 October 2026.
- Q2 2026 earnings call: Belén Garijo's first call as CEO (LSEG transcript)
- Twelve weeks in, Garijo says she has "completed the critical phase of my diagnosis": Sanofi has strong commercial execution (Q2 sales +17.8% CER, business EPS +33.3%) but must fix R&D productivity "with the right sense of urgency"; an enterprise-level strategy will be shared "over the coming months and latest by the end of the year".
- R&D diagnosis: "we need greater scientific rigor, fact-based decision-making, a stronger [...] governance, and more effective operations"; she blames setbacks on Phase 2-to-Phase 3 decisions that "start by dreaming on a target product profile that is not based on rigorous assumption", wants scientists to own go/no-go calls, and has launched an outside-in portfolio review (amlitelimab, itepekimab and balinatunfib already cut; "we don't have a target number to discontinue"). Paulo Fontoura becomes head of R&D in September; R&D spend will grow moderately, below sales, in the short term.
- BD and M&A will be intensified: "our appetite for bigger deals is an option" subject to strategic fit, science and financial guardrails; focus on disease areas where Sanofi is strong (dermatology, respiratory, rare diseases), with no barriers related to Regeneron to moving forward on M&A and, per Charmeil, "no urgency -- dramatic urgency" on timing. Roger, who now also owns BD, notes Sanofi invested €47bn in BD/M&A over eight years and "lost" about €7bn of it.
- Regeneron alliance is "of strategic importance"; Garijo found trust lacking and is rebuilding it with Manuela Buxo; options include adding assets from both sides and improving agility; the narrow information-sharing litigation does not block talks. On Dupixent, "Our current focus is Dupixent, one. Two, Dupixent. Three, Dupixent."
- China is a priority: "we have lost a bit of momentum in China"; Thomas Triomphe will lead China from 1 September, both to sell into a large-volume market and to in-license Chinese innovation. Rare diseases (top-2/3 position) are seen as a larger opportunity beyond genetic disorders; businesses that do not become growth platforms could be partnered or sold.
- 2030 ambition updated at today's less favourable rates: Dupixent around €25bn, pharma launches about €10bn (needs a ~15% CAGR versus ~27% like-for-like growth in H1; launches should reach €5.2-5.3bn in 2026 and are already profitable), vaccines about €9bn (down €1bn: half FX, half weaker US vaccination rates after the administration change). Dupixent patents run to 2046; the planning base case remains the March 2031 US compound patent expiry.
- Financial mechanics from the CFO: 2026 guidance raised to ~10% sales growth at CER with EPS slightly faster; Q2 Dupixent included "a couple of hundred millions" of one-off gross-to-net benefit (partly 340B controls, partly recurring); H2 growth will slow on tough comparables; Q3 vaccine sales expected down low-to-mid teens; Regeneron development reimbursement ended in Q2, leaving a €200m net BOI gap in 2027 (-€600m reimbursement, +€400m Amvuttra royalties); 2026 tax rate ~21%.
- Culture and organisation: a "performance-driven culture, greater accountability", empowered country leaders in "a de-globalizing market", and an eight-member ComEx from 1 September with three new members. On investor credibility: "we have, for a period of time, over promise and under deliver."
- Q1 2026 earnings call with interim CEO Olivier Charmeil, CFO François-Xavier Roger and R&D head Houman Ashrafian (LSEG transcript)
- Held one week before Belén Garijo's arrival, with Olivier Charmeil as interim CEO after Paul Hudson's departure (CEO 2019-2026): Q1 2026 sales €10.5bn, +13.6% at CER (about 12% like-for-like), business EPS +14%, BOI +10.9%, OpEx +7% but down 1.9 points as a share of sales; 2026 guidance of high single-digit sales growth with EPS slightly faster was confirmed (later raised in July).
- Growth drivers: launches were 14% of sales and grew 44% (about 22% excluding acquisitions): ALTUVIIIO €325m (+42%), Beyfortus €284m, Sarclisa €167m (+30%), Ayvakit €170m, Heplisav-B €46m since the February Dynavax closing; rare diseases nearly €1.8bn (+20%); vaccines €1.3bn; Dupixent approaching €4.2bn (+31%, flattered by a low US base), now nine indications and 1.4 million patients.
- First public Defend / Extend / Innovate plan for Dupixent's loss of exclusivity: patents from 2031 to 2045 (50+ US patents, none yet challenged) to be "vigorously" defended beyond the March 2031 US compound expiry; a four-weekly dosing option through a higher-dose asthma programme and a hyaluronidase co-formulation with a partner (studies from H2 2026); and new molecules through the Regeneron alliance, including an IL-4R alpha follow-on. Roger: the slide reflects investor appetite, "I don't think there is any defensive view on that matter."
- Capital allocation: Roger says Sanofi can invest up to €15bn in BD/M&A this year while keeping its AA rating, potentially €10bn more if it buys commercialised assets; priority areas are immunology, rare diseases and vaccines, with late-stage assets not excluded; BD did not pause pending the new CEO. About €400m of capital gains expected in 2026; the Brazilian generics unit Medley was signed for sale in March (closing around end-2026); the €1bn buyback was about to complete.
- Regeneron development reimbursement ends around Q2 2026: a negative BOI impact of about €400m in 2026 and a further ~€700m in 2027, which Sanofi says it will absorb while growing BOI in margin and absolute terms.
- Pipeline at the time: amlitelimab Phase 3 data presented at AAD with two cutaneous Kaposi's sarcoma cases among ~4,500 patients, management still "confident in the benefit risk" and planning an H2 2026 filing (later abandoned); lunsekimig positive Phase 2 in asthma and CRSwNP, Phase 3 next; duvakitug maintenance data; venglustat positive in Gaucher type 3 but failed in Fabry; itepekimab COPD Phase 3 decision pending with regulators and Regeneron; new in-licensing of rovadicitinib (Sino Biopharm) and a Kali Therapeutics T-cell engager.
- Charmeil's advice to the incoming CEO: "take some time to make the right diagnostic", then "be decisive"; the company has "considerably changed in the last 5 to 10 years", with better prioritisation and stronger US commercial capabilities. Buxo on competition: atopic dermatitis is "barely above 18% advanced therapy penetration", so new entrants expand the market.
Questions about Sanofi
What does Sanofi do?
Sanofi develops, makes and sells medicines and vaccines in immunology, rare diseases, neurology, oncology and vaccines; Dupixent is its largest product.
What is Sanofi's revenue?
FY2025 net sales were €43,626m, up 9.9% at constant exchange rates; H1 2026 net sales were €22,106m.
How many employees does Sanofi have?
74,846 at end-2025, after the transfer of Opella staff.
Who is Sanofi's CEO?
Belén Garijo has been CEO since 1 May 2026, succeeding Paul Hudson; François-Xavier Roger is CFO.
What is Sanofi's strategy?
Grow Dupixent and new launches, fix R&D productivity through a portfolio review, intensify BD and M&A in its strongest disease areas and regain momentum in China.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)